Evaluation of a prototype real-time PCR assay for carcinogenic human papillomavirus (HPV) detection and simultaneous HPV genotype 16 (HPV16) and HPV18 genotyping

Journal of Clinical Microbiology

Volumn 47, Issue 10, 2009, Pages 3344-3347

  Castle, Philip E ^a   Sadorra, Mark ^b   Lau, Tiffany ^b   Aldrich, Carrie ^b   Garcia, Francisco A R ^c   Kornegay, Janet ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ROCHE MOLECULAR SYSTEMS   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RISK; CARCINOGENICITY; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; UTERINE CERVIX CANCER; VIRUS DETECTION;

CERVIX UTERI; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

HUMAN PAPILLOMAVIRUS;

EID: 70349648503     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00725-09     Document Type: Article

References (27)

1. Bulkmans, N. W., J. Berkhof, L. Rozendaal, F. J. van Kemenade, A. J. Boeke, S. Bulk, F. J. Voorhorst, R. H. Verheijen, K. van Groningen, M. E. Boon, W. Ruitinga, M. van Ballegooijen, P. J. Snijders, and C. J. Meijer. 2007. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370:1764-1772.
2. Castle, P. E. 2008. Invited commentary: is monitoring of human papillomavirus infection for viral persistence ready for use in cervical cancer screening? Am. J. Epidemiol. 168:138-144.
3. Castle, P. E., J. Dockter, C. Giachetti, F. A. Garcia, M. K. McCormick, A. L. Mitchell, E. B. Holladay, and D. P. Kolk. 2007. A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer. Clin. Cancer Res. 13:2599-2605.
4. Castle, P. E., B. Fetterman, N. Poitras, T. Lorey, R. Shaber, and W. Kinney. 2009. Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet. Gynecol. 113:595-600.
5. Castle, P. E., P. E. Gravitt, D. Solomon, C. M. Wheeler, and M. Schiffman. 2008. Comparison of Linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study. J. Clin. Microbiol. 46:109-117.
6. Castle, P. E., C. Porras, W. G. Quint, A. C. Rodriguez, M. Schiffman, P. E. Gravitt, P. Gonzalez, H. A. Katki, S. Silva, E. Freer, L. J. Van Doorn, S. Jimenez, R. Herrero, and A. Hildesheim. 2008. Comparison of two PCR-based human papillomavirus genotyping methods. J. Clin. Microbiol. 46:3437-3445.
7. Castle, P. E., A. C. Rodriguez, R. D. Burk, R. Herrero, S. Wacholder, M. Alfaro, J. Morales, D. Guillen, M. E. Sherman, D. Solomon, M. Schiffman, et al. 2009. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ 339:b2569.
8. Castle, P. E., M. Sadorra, F. Garcia, E. B. Holladay, and J. Kornegay. 2006. Pilot study of a commercialized human papillomavirus (HPV) genotyping assay: comparison of HPV risk group to cytology and histology. J. Clin. Microbiol. 44:3915-3917.
9. Coutlee, F., D. Rouleau, P. Petignat, G. Ghattas, J. R. Kornegay, P. Schlag, S. Boyle, C. Hankins, S. Vezina, P. Cote, J. Macleod, H. Voyer, P. Forest, S. Walmsley, and E. Franco. 2006. Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the Linear array HPV genotyping test. J. Clin. Microbiol. 44:1998-2006.
10. Cuzick, J., C. Clavel, K. U. Petry, C. J. Meijer, H. Hoyer, S. Ratnam, A. Szarewski, P. Birembaut, S. Kulasingam, P. Sasieni, and T. Iftner. 2006. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer 119:1095-1101. (Pubitemid 44116919)
11. Dillner, J., M. Rebolj, P. Birembaut, K. U. Petry, A. Szarewski, C. Munk, S. de Sanjose, P. Naucler, B. Lloveras, S. Kjaer, J. Cuzick, M. van Ballegooijen, C. Clavel, T. Iftner, et al. 2008. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 337:a1754.
12. Gravitt, P. E., M. Schiffman, D. Solomon, C. M. Wheeler, and P. E. Castle. 2008. A comparison of linear array and hybrid capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study. Cancer Epidemiol. Biomarkers Prev. 17:1248-1254.
13. Khan, M. J., P. E. Castle, A. T. Lorincz, S. Wacholder, M. Sherman, D. R. Scott, B. B. Rush, A. G. Glass, and M. Schiffman. 2005. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl. Cancer Inst. 97:1072-1079.
14. International Agency for Research on Cancer (IARC), World Health Organization. 2005. IARC handbooks of cancer prevention: cervix cancer screening, vol.10. IARC Press, Lyon, France.
15. Mayrand, M. H., E. Duarte-Franco, I. Rodrigues, S. D. Walter, J. Hanley, A. Ferenczy, S. Ratnam, F. Coutlee, and E. L. Franco. 2007. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N. Engl. J. Med. 357:1579-1588.
16. Meijer, C. J., J. Berkhof, P. E. Castle, A. T. Hesselink, E. L. Franco, G. Ronco, M. Arbyn, F. X. Bosch, J. Cuzick, J. Dillner, D. A. Heideman, and P. J. Snijders. 2009. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int. J. Cancer 124:516-520.
17. Munoz, N., F. X. Bosch, S. de Sanjose, R. Herrero, X. Castellsague, K. V. Shah, P. J. Snijders, and C. J. Meijer. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348:518-527.
18. Naucler, P., W. Ryd, S. Tornberg, A. Strand, G. Wadell, K. Elfgren, T. Radberg, B. Strander, O. Forslund, B. G. Hansson, E. Rylander, and J. Dillner. 2007. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N. Engl. J. Med. 357:1589-1597.
19. Ronco, G., N. Segnan, P. Giorgi-Rossi, M. Zappa, G. P. Casadei, F. Carozzi, P. P. Dalla, M. A. Del, S. Folicaldi, A. Gillio-Tos, G. Nardo, C. Naldoni, P. Schincaglia, M. Zorzi, M. Confortini, and J. Cuzick. 2006. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J. Natl. Cancer Inst. 98:765-774.
20. Saslow, D., C. D. Runowicz, D. Solomon, A. B. Moscicki, R. A. Smith, H. J. Eyre, and C. Cohen. 2002. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J. Clin. 52:342-362.
21. Schiffman, M., R. Herrero, A. Hildesheim, M. E. Sherman, M. Bratti, S. Wacholder, M. Alfaro, M. Hutchinson, J. Morales, M. D. Greenberg, and A. T. Lorincz. 2000. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA 283:87-93. (Pubitemid 30038388)
22. Smith, J. S., L. Lindsay, B. Hoots, J. Keys, S. Franceschi, R. Winer, and G. M. Clifford. 2007. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int. J. Cancer 121:621-632.
23. Stevens, M. P., S. M. Garland, E. Rudland, J. Tan, M. A. Quinn, and S. N. Tabrizi. 2007. Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results. J. Clin. Microbiol. 45:2130-2137.
24. Stoler, M. H., P. E. Castle, D. Solomon, and M. Schiffman. 2007. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am. J. Clin. Pathol. 127:1-3.
25. Szarewski, A., L. Ambroisine, L. Cadman, J. Austin, L. Ho, G. Terry, S. Liddle, R. Dina, J. McCarthy, H. Buckley, C. Bergeron, P. Soutter, D. Lyons, and J. Cuzick. 2008. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol. Biomarkers Prev. 17:3033-3042.
26. Wright, T. C., Jr., L. S. Massad, C. J. Dunton, M. Spitzer, E. J. Wilkinson, and D. Solomon. 2007. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am. J. Obstet. Gynecol. 197:346-355.
27. Wright, T. C., Jr., and M. Schiffman. 2003. Adding a test for human papillomavirus DNA to cervical-cancer screening. N. Engl. J. Med. 348:489-490.